

**EKF Diagnostics Holdings plc
("EKF" or the "Company")**

Directors' Exercise of Options

EKF (AIM: EKF), the growing in-vitro diagnostics company, announces that today it has received notification of the following exercise of options today over Ordinary Shares of one pence each in the Company (the "Ordinary Shares") by Adam Reynolds (Non-Executive Director) and Paul Foulger (Company Secretary) all at an exercise price of 1 pence per Ordinary Share.

- Adam Reynolds exercised options over 1,325,488 Ordinary Shares.
- Paul Foulger exercised options over 1,325,488 Ordinary Shares.

These options were granted to Mr Reynolds and Mr Foulger as part of the Company's Long Term Incentive Plan and neither Director has any immediate plans to sell the shares.

Application will be made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 2,650,976 new Ordinary Shares to AIM will become effective on, or around, 12 April 2012.

After the exercise of options, and the Admission of the new Ordinary Shares to AIM, Adam Reynolds will hold 3,256,153 Ordinary Shares representing 1.3 per cent. of the Company's issued share capital and Paul Foulger will hold 3,138,652 Ordinary Shares representing 1.2 per cent. of the Company's issued share capital.

Enquiries:

EKF Diagnostics Holdings plc
David Evans, Executive Chairman
Julian Baines,
CEO

Tel: 029 2071 0570
Mob: 07740 084 452
Mob: 07788 420 859

Canaccord Genuity Limited
Jamie Adams
Mark Dickenson
Lucy Tilley

Tel: 020 7523 8000

Walbrook PR Limited
Paul McManus
Fiona Henson

Tel: 020 7933 8780
Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com
Mob: 07886 335 992 or fiona.henson@walbrookpr.com

About EKF Diagnostics Holdings plc

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Company has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010 for a maximum of £5.41m), Argutus Medical Limited (acquired in December 2010 for £2.18m) and Stanbio Laboratory L.P. (acquired in June 2011 for a maximum of US\$25.5m).

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focused on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo_Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

For more information please visit the website: www.ekfdiagnostics.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange

END

RDSIIMFTMBAMBJT admin Directors' Exercise of Options 20008191 A Thu, 04/05/2012 - 07:00
Directors' Dealings EKF